Patents Assigned to Children's Medical Center Corporation
  • METHODS AND COMPOSITIONS FOR TREATING ASTHMA
    Publication number: 20220033489
    Abstract: Described herein are methods and compositions for treating asthma. Aspects of the invention relates to administering to a subject an agent that inhibits IL-6 signaling. Another aspect of the invention relates to administering the anti-IL-6R antibody, tocilizumab, to a subject in need thereof.
    Type: Application
    Filed: December 4, 2019
    Publication date: February 3, 2022
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Talal Amine CHATILA, Hani HARB, Brittany ESTY, Wanda PHIPATANAKUL, Lisa M. BARTNIKAS
  • Non-invasive measurement to predict post-surgery anterior cruciate ligament success
    Patent number: 11234657
    Abstract: The current subject matter provides a tool for evaluating the risk of failure or the likelihood of success of surgery of healing ligaments and tendons in the body. In some embodiments, a region of a scan comprising one or more of an anterior cruciate ligament (ACL) or an ACL graft can be defined. A magnetic resonance (MR) imaging data set can be obtained. MR parameters characterizing a size and a quality of the ACL or ACL graft can be derived using the MR data. The MR parameters can be used as inputs to a predictive model. A score characterizing a likelihood of failure of the ACL or ACL graft in a human patient can be generated using the predictive model.
    Type: Grant
    Filed: May 1, 2018
    Date of Patent: February 1, 2022
    Assignees: Rhode Island Hospital, Children's Medical Center Corporation
    Inventors: Braden C. Fleming, Martha M. Murray
  • Methods and compositions for the inhibition of TRPV4
    Patent number: 11236147
    Abstract: TRPV4 activation increases vascular permeability and can be triggered by both chemical and mechanical cues. This activation of TRPV4 can contribute to a number of pathological conditions, e.g., edema, inflammation, hypertension, and/or hyperalgesia. Described herein are methods and compositions relating to inhibition of mechanically-induced TRPV4 activation, e.g., for the treatment of pulmonary edema, edema, inflammation, hypertension, and/or hyperalgesia.
    Type: Grant
    Filed: July 13, 2018
    Date of Patent: February 1, 2022
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Donald E. Ingber, Mariko Kobayashi
  • Immunogens and methods for discovery and screening thereof
    Patent number: 11235047
    Abstract: The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune response. The present application is also directed to pneumococcal T-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof. The present invention also encompasses use of the pneumococcal immunogens for diagnostic purposes to identify a subject with a pneumococcal infection.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: February 1, 2022
    Assignee: CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Richard Malley, Yingjie Lu, Kristin L. Moffitt
  • ANTIBACTERIAL COMPOUNDS AND USES THEREOF
    Publication number: 20220023270
    Abstract: Provided herein are compositions and methods for the treatment of infections resulting from antibiotic-resistant strains of bacteria.
    Type: Application
    Filed: December 5, 2019
    Publication date: January 27, 2022
    Applicant: The Children's Medical Center Corporation
    Inventors: Paula I. WATNICK, Julie Szu YU
  • MYBPC3 POLYPEPTIDES AND USES THEREOF
    Publication number: 20220023384
    Abstract: Provided herein are compositions and methods for treating a disorder associated with abnormal RYR2 function (e.g., arrhythmia or heart failure). In some embodiments, method comprises administering to a subject in need thereof an effective amount of a polypeptide comprising a C-terminal domain of Cardiac Myosin binding protein C (MYBPC3) or a nucleic acid or an rAAV encoding such polypeptide.
    Type: Application
    Filed: July 8, 2021
    Publication date: January 27, 2022
    Applicant: Children's Medical Center Corporation
    Inventors: William T. Pu, Fujian Lu, Vassilios Bezzerides
  • PURIFIED MESENCHYMAL STEM CELL EXOSOMES AND USES THEREOF
    Publication number: 20220023347
    Abstract: Provided herein are isolated exosomes from mesenchymal stem cells (MSC). Such isolated exosomes are substantially CT free of contaminants and are therapeutically active in treating various diseases (e.g., lung diseases such as BPD). The isolated MSC exosomes are identified by one or more protein markers described herein. Methods of purifying such MSC exosomes are also provided.
    Type: Application
    Filed: August 15, 2018
    Publication date: January 27, 2022
    Applicant: Children's Medical Center Corporation
    Inventors: S. Alexander Mitsialis, Stella Kourembanas
  • Biochemically stabilized HIV-1 Env trimer vaccine
    Patent number: 11229696
    Abstract: Stabilized trimers of a clade A strain and a clade C strain of HIV-1 are provided. Broadly neutralizing antisera against HIV-1, methods of making broadly neutralizing antisera against HIV-1, broadly neutralizing vaccines against HIV-1, as well as methods of treating subjects infected with HIV, preventing HIV infection, and inhibiting HIV-mediated activities are also provided.
    Type: Grant
    Filed: April 27, 2020
    Date of Patent: January 25, 2022
    Assignees: Beth Israel Deaconess Medical Center, Inc., Children's Medical Center Corporation
    Inventors: Stephen C. Harrison, Bing Chen, Dan Barouch, Joseph P. Nkolola, Michael Scott Seaman
  • PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS
    Publication number: 20220016046
    Abstract: The invention provides compounds, compositions, methods, and kits for the treatment or neurogenic inflammation.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 20, 2022
    Applicants: Children's Medical Center Corporation, President and Fellows of Harvard College, The General Hospital Corporation
    Inventors: Clifford J. Woolf, Bruce P. Bean
  • THERAPEUTIC GENE EDITING FOR ELANE-ASSOCIATED DISEASE
    Publication number: 20220017865
    Abstract: Provided herein are reagents and methods for targeting the ELANE gene for inhibition. Further provided herein is a method for producing a progenitor cell or a population of progenitor cells having decreased ELANE mRNA or protein expression.
    Type: Application
    Filed: November 27, 2019
    Publication date: January 20, 2022
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, UNIVERSITY OF MASSACHUSETTS
    Inventors: Josias Brito FRAZÃO, Scot A. WOLFE, Daniel E. BAUER, Shuquan RAO, Peter E. NEWBURGER
  • CALMODULIN INHIBITORS, CHK2 INHIBITORS AND RSK INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMAPATHIES
    Publication number: 20220008420
    Abstract: The present invention relates to methods, compositions and kits for treatment of ribosomal disorders and ribosomopathies, e.g. Diamond Blackfan anemia (DBA). In some embodiments, the invention relates to the use of novel classes of compounds, i.e. inhibitors of RSK (p90S6K); inhibitors of p70S6K; and inhibitors of rps6, to treat ribosomal disorders and ribosomopathies. In some embodiments, the invention relates to the use of specific Chk2 inhibitors and to the use of specific phenothiazine derivatives to treat ribosomal disorders and ribosomopathies, e.g. DBA.
    Type: Application
    Filed: February 12, 2021
    Publication date: January 13, 2022
    Applicants: THE CHILDREN'S MEDICAL CENTER CORPORATION, DANA-FARBER CANCER INSTITUTE, INC.
    Inventors: James BRADNER, Jun QI, Dennis BUCKLEY, Leonard I. ZON, Elizabeth MACARI
  • APPARATUSES FOR CLEANING CATHETER PORTS
    Publication number: 20220008710
    Abstract: Methods and apparatus for cleaning a central venous catheter port are disclosed. An apparatus includes a body, a coupling configured to connect the body to the hub, a cleaning cap coupled to the body, and an actuator disposed within the body for rotating and translating the cap relative to the hub. The cleaning cap includes a cap body defining a cavity and a cleaning member disposed within the cavity, the cleaning member having threads that engage with the threads on the hub.
    Type: Application
    Filed: June 7, 2021
    Publication date: January 13, 2022
    Applicant: Children's Medical Center Corporation
    Inventors: John Kheir, Pierre DuPont, Asghar Ataollahi, Sarah Ward Goldberg, Brian D. Polizzotti
  • Modulators of telomere disease
    Patent number: 11220689
    Abstract: The disclosure relates to treating and diagnosing telomere diseases, and methods of screening agents for treating and diagnosing telomere diseases.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: January 11, 2022
    Assignee: Children's Medical Center Corporation
    Inventors: Suneet Agarwal, Diane Moon, Baris Boyraz, Matthew Segal
  • ADAMTS13-CONTAINING COMPOSITIONS HAVING THROMBOLYTIC ACTIVITY
    Publication number: 20220002703
    Abstract: This invention relates to a pharmaceutical composition having thrombolytic activity comprising ADAMTS13, and to methods for treating or preventing a disorder associated with the formation and/or the presence of one or more thrombus and to methods of disintegrating one or more thrombus in a patient in need thereof.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 6, 2022
    Applicants: TAKEDA PHARMACEUTICAL COMPANY LIMITED, CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Denisa D. Wagner, Anil Kumar Chauhan, Friedrich Scheiflinger, Barbara Plaimauer
  • HIGH-AFFINITY HUMAN ACE2 CONSTRUCT FOR USE IN DIAGNOSING AND TREATING CORONAVIRUSES
    Publication number: 20220002701
    Abstract: Provided herein, in some aspects, are polypeptide monomers comprising an angiotensin-converting enzyme 2 (ACE2) ectodomain and an oligomerization domain. Also provided herein are oligomeric complexes comprising ACE2 monomers. Methods of using such to monomers and oligomeric complexes for the diagnosis, prevention, and treatment of viral infections such as the coronavirus are also provided.
    Type: Application
    Filed: May 19, 2021
    Publication date: January 6, 2022
    Applicant: Children's Medical Center Corporation
    Inventors: Bing Chen, Tianshu Xiao, Yongfei Cai, Jun Zhang
  • METHODS AND COMPOSITIONS FOR TREATING OR PREVENTING THE DEVELOPMENT OF FOOD ALLERGIES
    Publication number: 20220000976
    Abstract: Described herein are methods and compositions for treating or preventing a food allergy. Aspects of the invention relates to administering to a subject an agent that induces a regulatory T cell, or population thereof, that expresses ROR yt. Another aspect of the invention relates to administering a fecal matter transplant to a subject having reduced ROR yt-expressing regulatory T cells to treat or prevent a food allergy.
    Type: Application
    Filed: November 8, 2019
    Publication date: January 6, 2022
    Applicant: THE CHILDREN'S MEDICAL CENTER CORPORATION
    Inventors: Talal A. CHATILA, Azza ABDEL-GADIR, Emmanuel Stephen VICTOR, Rima RACHID
  • Gasket with multi-leaflet valve for surgical port apparatus
    Patent number: 11213316
    Abstract: A gasket for creating a fluid seal in a medical device includes a flexible base, a flexible hollow body, and a multi-leaflet valve. The flexible hollow body extends along an axis from a hole defined in the flexible base. The flexible hollow body is configured to have a relaxed state in which a cross section of the flexible hollow body has a first shape and a compressed state in which the cross section of the flexible hollow body has a second shape. The multi-leaflet valve is disposed in the flexible hollow body. The compressed state causes the multi-leaflet valve to close to increase (a) a first threshold force or a first threshold pressure differential needed to open the multi-leaflet valve in a distal direction and (b) a second threshold force or a second threshold pressure differential needed to open the multi-leaflet valve in a proximal direction.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: January 4, 2022
    Assignee: The Children's Medical Center Corporation
    Inventors: Anthony Maiorano, Jeffrey C. Cerier, Jake Ganem
  • Vaccines and compositions against
    Patent number: 11207375
    Abstract: Streptococcus pneumoniae is a major health concern, especially in very young, elderly, or immunocompromised patients. The present disclosure provides, inter alia, certain highly effective vaccines and pharmaceutical compositions in Streptococcus pneumoniae. The antigens may be used therapeutically or prophylactically.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: December 28, 2021
    Assignees: Genocea Biosciences, Inc., Children's Medical Center Corporation
    Inventors: Todd Gierahn, Richard Malley
  • Methods of epigenetic analysis
    Patent number: 11208683
    Abstract: The present invention provides for methods of epigenetic analysis. In some cases, the methods may include obtaining a sample comprising a nucleic acid sequence. In some cases, the nucleic acid sequence may comprise one or more epigenetic marks. The methods may include performing a sequencing. The methods may include distinguishing a hydroxymethylated base from a methylated base.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: December 28, 2021
    Assignees: The Children's Medical Center Corporation, The United States of America, As Represented by the Secretary, Department of Health & Human Services
    Inventors: Anjana Rao, Mamta Tahiliani, Kian Peng Koh, Suneet Agarwal, Aravind Iyer
  • Nucleic acid-based linkers for detecting and measuring interactions
    Patent number: 11198900
    Abstract: The invention provides compositions comprising nucleic acid complexes for use in monitoring binding interactions and in measuring association and/or dissociation kinetics, detecting analytes including low concentration analytes, and screening library members. In some instances, the nucleic acid complexes are double-stranded nicked nucleic acids comprising a scaffold nucleic acid hybridized to one or more oligonucleotides. In some instances, a first, a second, a third, and optionally a fourth oligonucleotide are linked to moieties that are known to interact with each other or which are suspected of interacting with each other or of interacting with a common moiety such as an analyte. Changes in topology of the complex are used to determine the binding interactions of the various binding partners.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: December 14, 2021
    Assignees: Children's Medical Center Corporation, President and Fellows of Harvard College
    Inventors: Mounir Ahmad Koussa, Kenneth Anders Halvorsen, Andrew Ward, Wesley Philip Wong